SCHEMBL24933211

SCHEMBL24933211

NC(=O)c1cc(-c2ccc(OCc3ccnnc3)cc2)c(C(F)(F)F)[nH]c1=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 3/20 0.37
HDAC3 O15379 2/20 0.36
PARP1 P09874 2/20 0.36
HDAC4 P56524 2/20 0.36
HDAC1 Q13547 2/20 0.36
HDAC7 Q8WUI4 2/20 0.36
HDAC2 Q92769 2/20 0.36
HDAC10 Q969S8 2/20 0.36
HDAC11 Q96DB2 2/20 0.36
HDAC8 Q9BY41 2/20 0.36
HDAC6 Q9UBN7 2/20 0.36
HDAC9 Q9UKV0 2/20 0.36
HDAC5 Q9UQL6 2/20 0.36
HSD17B1 P14061 5/20 0.35
HSD17B2 P37059 5/20 0.35
PRKAB2 O43741 1/20 0.35
PRKAG1 P54619 1/20 0.35
PRKAA2 P54646 1/20 0.35
PRKAA1 Q13131 1/20 0.35
PRKAG3 Q9UGI9 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24933646 0.89 MAOB (0.44) MAOBHDAC3PARP1HDAC4HDAC1
SCHEMBL24933190 0.88 PRKAB2 (0.48) MAOBPRKAB2PRKAG1PRKAA2PRKAA1
SCHEMBL24933508 0.86 MRGPRX4 (0.41) MAOBHDAC3PARP1HDAC4HDAC1
SCHEMBL30240820 0.86 MAOB (0.39) MAOBHDAC3PARP1HDAC4HDAC1
SCHEMBL24933804 0.86 MAOB (0.39) MAOBHDAC3PARP1HDAC4HDAC1
SCHEMBL24933385 0.86 PARP1 (0.39) MAOBHDAC3PARP1HDAC4HDAC1
SCHEMBL24933463 0.86 HSD17B1 (0.41) MAOBHDAC3PARP1HDAC4HDAC1
SCHEMBL24933815 0.86 NPC1 (0.43) MAOBHDAC3PARP1HDAC4HDAC1
SCHEMBL30240772 0.86 NPC1 (0.43) MAOBHDAC3PARP1HDAC4HDAC1
SCHEMBL24933349 0.85 GSTP1 (0.50) MAOBHSD17B1HSD17B2CHEK2GSTP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4373809-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS Novartis AG (CH) 2024-05-29 EP claimed
CN-117980292-A Substituted pyridone compounds for the treatment of orthomyxoviral infections 诺华股份有限公司 2024-05-03 CN claimed
WO-2023002443-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS NOVARTIS AG (CH) 2023-01-26 WO claimed
EP-4373809-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS Novartis AG (CH) 2024-05-29 EP disclosed
CN-117980292-A Substituted pyridone compounds for the treatment of orthomyxoviral infections 诺华股份有限公司 2024-05-03 CN disclosed
WO-2023002443-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS NOVARTIS AG (CH) 2023-01-26 WO disclosed
WO-2023002443-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS NOVARTIS AG (CH) 2023-01-26 WO disclosed